Sanofi Aventis Us Company Profile

✉ Email this page to a colleague

SANOFI AVENTIS US has one hundred and twenty-two approved drugs.

There are ten US patents protecting SANOFI AVENTIS US drugs.

There are two hundred and seventeen patent family members on SANOFI AVENTIS US drugs in fifty-two countries and one hundred and fifteen supplementary protection certificates in nineteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	CERUBIDINE	daunorubicin hydrochloride	INJECTABLE;INJECTION	061876-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	HYDROXYSTILBAMIDINE ISETHIONATE	hydroxystilbamidine isethionate	INJECTABLE;INJECTION	009166-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-001	Oct 30, 1992		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	INOCOR	inamrinone lactate	INJECTABLE;INJECTION	018700-001	Jul 31, 1984		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-003	Aug 3, 2010	AP	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	SLO-PHYLLIN	theophylline	TABLET;ORAL	085204-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	INTAL	cromolyn sodium	CAPSULE;INHALATION	016990-001	Approved Prior to Jan 1, 1982	3,686,412	⤷ Sign Up
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991	4,359,578	⤷ Sign Up
Sanofi Aventis Us	SKELID	tiludronate disodium	TABLET;ORAL	020707-001	Mar 7, 1997	4,876,248	⤷ Sign Up
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998	4,351,841	⤷ Sign Up
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	5,459,163	⤷ Sign Up
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-003	Mar 27, 1998	4,692,435	⤷ Sign Up
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-003	Nov 17, 2006	5,716,988*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	12.5 mg	➤ Subscribe	2006-01-19
➤ Subscribe	Tablets	150 mg/12.5 mg and 300 mg/12.5 mg	➤ Subscribe	2004-11-10
➤ Subscribe	Tablets	75 mg, 150 mg and 300 mg	➤ Subscribe	2004-05-25
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-03-04
➤ Subscribe	Injection	40 mg/mL, 0.5 mL and 2 mL vials	➤ Subscribe	2009-06-30
➤ Subscribe	For Injection	50 mg/vial and 100 mg/vial	➤ Subscribe	2007-02-09
➤ Subscribe	Injection	5 mg/mL, 40 mL vial	➤ Subscribe	2011-03-23
➤ Subscribe	Extended-release Tablets	6.25 mg	➤ Subscribe	2006-02-24
➤ Subscribe	Tablets	7 mg and 14 mg	➤ Subscribe	2016-09-12
➤ Subscribe	Tablets	300 mg/25 mg	➤ Subscribe	2006-06-06
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2013-07-01
➤ Subscribe	Injection	5 mg/mL, 10 mL and 20 mL vials	➤ Subscribe	2007-02-09
➤ Subscribe	Injection	200 mg/40 mL	➤ Subscribe	2007-07-16
➤ Subscribe	Injection	100 mg/mL, 3 mL vials	➤ Subscribe	2006-12-07

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1667986	C20130017 00077	Estonia	⤷ Sign Up	PRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011
0454511	C980039	Netherlands	⤷ Sign Up	PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAA T; REGISTRATION NO/DATE: EU/1/97/046/001 - 009 19970827
3300601	22C1034	France	⤷ Sign Up	PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
0454511	C990006	Netherlands	⤷ Sign Up	PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAAT, EN HYDROCHLOORTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 - EU/1/98/086/006 19981015
1381356	C01381356/01	Switzerland	⤷ Sign Up	FORMER OWNER: AVENTISUB LLC, US
2768484	CA 2019 00051	Denmark	⤷ Sign Up	PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827
2768484	2019/054	Ireland	⤷ Sign Up	PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.